Filing Flows › Biocryst Pharmaceuticals (BCRX) › Q2 2026 › vs Q2 2025
Biocryst Pharmaceuticals (BCRX) Q2 2026 vs Q2 2025 (year over year)
Biocryst Pharmaceuticals's revenue rose $54.9M (+34%) from $163M in Q2 2025 to $218M in Q2 2026. The biggest changes: License and other revenues +$59.8M (66×); ORLADEYO +$1.4M (+0.9%). Operating margin 45.1% against 18.2% (+26.9 pts).
Biocryst Pharmaceuticals, Q2 2026: revenue $218M (+34% year over year), operating margin 45.1%, net earnings $78.4M, operating cash flow $104M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 45.1% | 18.2% | +26.9 pts |
| Net margin | 35.9% | 3.1% | +32.8 pts |
| Free cash flow margin | 47.7% | 25.2% | +22.5 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| ORLADEYO | $158M | $157M | $1.4M | +0.9% |
| License and other revenues | $60.7M | $923K | $59.8M | 66× |
| Revenue | $218M | $163M | $54.9M | +34% |
| Operating profit | $98.5M | $29.8M | $68.7M | +231% |
| Costs & expenses | $120M | $134M | −$13.8M | -10% |
| Pre-tax earnings | $79.5M | $6.5M | $73.0M | 12× |
| Other expense, net | $19.0M | $23.3M | −$4.3M | -18% |
| Cost of revenue | $3.8M | $2.8M | $1.0M | +37% |
| Research & development | $52.0M | $43.4M | $8.6M | +20% |
| SG&A | $64.0M | $87.4M | −$23.4M | -27% |
| Net earnings | $78.4M | $5.1M | $73.3M | 15× |
| Income tax | $1.1M | $1.4M | −$322K | -23% |
| Depreciation & amortization | $513K | $329K | $184K | +56% |
| Share-based compensation | $14.7M | $21.3M | −$6.6M | -31% |
| Working capital & other | $10.7M | $14.6M | −$3.8M | -26% |
| Operating cash flow | $104M | $41.3M | $63.0M | +153% |
| Free cash flow (OCF − capex) | $104M | $41.1M | $63.0M | +153% |
| Capital expenditures | $209K | $179K | $30K | +17% |
Questions
How much did Biocryst Pharmaceuticals's revenue grow year over year in Q2 2026?
Biocryst Pharmaceuticals's revenue rose $54.9M (+34%) from $163M in Q2 2025 to $218M in Q2 2026.
What drove Biocryst Pharmaceuticals's revenue change in Q2 2026?
License and other revenues +$59.8M (66×); ORLADEYO +$1.4M (+0.9%).